Healthcare Capital & Connections Summit


September 11 - 13, 2018
Shanghai, China

Register Now
English | Chinese (中文)


2018 Summit Details


Summit speakers and attendee information will be updated regularly to help you plan your 2018 Summit schedule.

  1. Agenda

    2018 SUMMIT AGENDA

    We continue to add finalize sessions and speakers. Visit this webpage for updates.

    Day One: Tuesday, September, 11, 2018

     

    Day Three: Thursday, September 13, 2018

    13:00 - 17:00 Zhangjiang Pharma Valley Site Visit   9:00 - 9:15 Welcome and Opening Remarks

    18:30 - 20:00 

    Welcome Reception hosted by O’Melveny
      9:15 - 10:00 Lessons in Cross-Border M&A and Financing: What You Need to Know from Those Who Have Walked the Path

    Day Two: Wednesday, September 12, 2018

      10:00 - 10:30 Break

    9:00 - 9:15

    Welcome and Opening Remarks

      10:30 - 11:15 Politics and Global Trade: Implications for Cross-Border Deal Making and Investment
    9:15 - 10:00 China Innovation: Is the Era of "Me Too" Over?   11:15 - 12:15 The Impact of Changing CNDA Policy on Cross-Border Deal Making
    10:15 - 11:00 The Hong Kong Exchange: Implications for the Global Life Sciences Innovation Ecosystem   12:15 - 13:30 Lunch hosted by Piper Jaffray
    11:00 - 11:45 Which Western Therapeutic Markets Will Translate to China...and Which Won't?   13:30 - 16:30 1 on 1 Meetings & Company Presentations
    11:45 - 12:30 The US Perspective: Key Priorities for U.S. Executivies in China      
    12:30 - 13:30 Lunch hosted by DLA Piper      
    13:30 - 16:30 Company Presentations and 1 on 1 Meetings      
    18:30 - 20:30 Dinner hosted by SPD Silicon Valley Bank      
  2. Speakers

    2018 SUMMIT SPEAKERS

    Katherine Anderson
    Senior Market Manager
    Silicon Valley Bank

    Katherine Andersen is a senior market manager covering U.S. healthcare corporate finance and the East/Central regions for Life Science. Previously, she was a senior vice president at Wells Fargo Bank, leading life science business development and relationship management efforts. Before that, at Wells Fargo Capital Finance, she focused on front-end business development and underwriting of middle market structured loans. She has held various positions at Affiliated Managers Group, Merrill Lynch, GE Corporate Audit Staff and GE Capital.

    She currently serves on the Finance Advisory Board for Virginia Polytechnic Institute and State University and the Corporate Council for the American Cancer Society’s Hope Lodge.

    Ms. Andersen holds a bachelor’s degree in finance and economics from Virginia Tech. She has also completed Dartmouth’s Tuck Executive Leadership and Strategic Impact Program, Wells Fargo’s Transformational Leadership Program, the Program on Negotiation at Harvard Law School and the GE Capital Financial Management Program.

    Mark Bach
    Vice President and Head of Asia Pacific Medical Sciences, China Innovation Leader
    Johnson & Johnson

    As head of Asia Pacific Medical Sciences since 2012, Mark Bach leads an Asia Pacific team of over 1,400 science professionals in Drug Discovery, Clinical Development, and Medical Affairs dedicated to delivering transformational healthcare innovation.

    In September 2014, Mark took on the additional responsibility of leading a fast-growing Janssen R&D and Medical Affairs team in China, one of the Company’s four global hubs for drug discovery and development. In his two roles, Mark has focused on building organizational capabilities and eliminating ‘drug lag’ to bring important new medicines to patients in need across the region.

    Mark joined Janssen in 2010 as Vice President and Head of the Japan Medical Organization, where he led the team responsible for scientific and medical activity, including R&D, regulatory, drug safety, scientific affairs, healthcare policy, market access, and pricing. During Mark’s tenure, he led major change initiatives that drove substantial increases in productivity and a one-team culture around a common vision and purpose. Mark joined the pharmaceutical industry in 1993 with Merck & Co., where he held positions of increasing responsibility in global, regional and Japan-based roles over 16 years, including the roles of Deputy Head of Clinical Development in Japan and Head of Global Clinical Research Operations.

    Mark received his Ph.D. in Pathology from the University of Chicago and his medical degree from the Baylor College of Medicine, where he also served his residency in pediatrics. He was trained as a Pediatric Endocrinologist at the U.S. National Institutes of Health.

    Michael Chan
    Senior Vice President
    Market Development Division, HKEX

    Michael Chan is senior vice president of the Market Development Division of HKEX, where he heads the international issuer marketing efforts. He focuses mainly on market development work, promoting the Hong Kong listing platform, and origination work, attracting international companies to list in Hong Kong. In addition to leading the marketing efforts globally and working closely with prospects and constituents, he often speaks and serves as panelist and keynote speaker at major local and international conferences and events. He has more than 17 years of experience in financial services and regulatory work.

    Previously, Mr. Chan worked in the Listing Division of HKEX for eight years, covering compliance, corporate governance, regulatory matters and initial public offerings.

    Prior to joining HKEX, he worked at various financial institutions in corporate finance and business development.

    Chip Clark
    President and Chief Executive Officer
    Genocea

    Chip Clark has been Genocea’s president and CEO since 2011, after briefly serving as its chief business officer. He has also served on the Genocea Board of Directors since 2011.

    Prior to Genocea, he served as chief business officer at Vanda Pharmaceuticals, a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company’s strategic and business development activities and played a central role in raising more than $400 million through business development deals and equity financings. Previously, he was a principal at Care Capital, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial and strategic roles at SmithKline Beecham (now GlaxoSmithKline).

    Mr. Clark holds a bachelor of arts degree from Harvard University and a master of business administration degree from the Wharton School of the University of Pennsylvania.

    Lifei Cheng
    Vice President, Strategy — Business Development and Ventures
    Medtronic

    Lifei Cheng, Ph.D., is the vice president of business development and ventures at Medtronic Greater China. His team sources, evaluates and executes mergers and acquisitions, venture investments and local partnerships. He established the Medtronic–Sequoia China venture fund, dedicated to investments in early-stage medical technology and service startups. Recently, his team started mLab, an open innovation accelerator, to provide funding and resources to early-stage startups and accelerate product development and commercialization.

    Before joining Medtronic, Dr. Cheng headed up business development at MSD/Merck China. He built and led a cross-function, cross-border team to generate profitable growth through local investment and partnership.

    Dr. Cheng holds an executive master of business administration degree in finance from the Wharton School at the University of Pennsylvania. His Ph.D. in engineering and economics is from Carnegie Mellon University. He graduated from Tsinghua University with dual bachelor of science degrees in engineering and business.

    Andy Clayton
    Managing Director & Head of Asia Healthcare Investment Banking
    Piper Jaffray

    Andy Clayton is a managing director and head of Asia healthcare investment banking. He has more than 15 years of healthcare investment banking experience. Clayton has successfully completed more than 40 transactions across a broad range of products, including debt, equity, and mergers and acquisitions.

    Prior to joining Piper Jaffray, Clayton was a senior calling officer at Jefferies, where he was dedicated to serving Asian healthcare clients. Previously, he was a director in the UBS Investment Bank healthcare group, where he spent five years serving clients in both the U.S. and Asian markets. Before joining UBS in 2004, Clayton worked as a director of corporate development at SunGard Data Systems, where he focused on executing M&A transactions. Clayton received a Master of Business Administration degree from The University of Chicago Booth School of Business and a bachelor’s degree from Williams College.

    Dan Croteau
    CEO 
    Surgicial Specialties Corporation

    In October 2017 Dan Croteau joined Surgical Specialties Corporation as its CEO. Surgical Specialties Corporation is a private equity backed company that specializes in high performance wound closure products and surgical knives.

    From January, 2011 to March, 2017 Dan served as the CEO of Vention Medical, a private equity backed provider of medical device design, engineering, component manufacturing and finished device assembly services for single use interventional and surgical medical devices. The company was sold in two transactions to Nordson Corporation and MedPlast Corporation in March 2017.

    Previously Dan served as the President of FlexMedical, the medical division of Flex (Nasdaq FLEX), for almost 5 years, building a global manufacturing and supply chain division focused on disposable medical devices, diagnostic instrumentation, and drug delivery devices.

    Prior to that, Dan served in a variety of executive roles in the medical device industry; most notably as Executive Vice President and General Manager of Accellent (now part of Integer/Greatbach); and as a Senior Vice President of Medsource Technologies, which was merged in 2005 with UTI Corporation to form Accellent. Prior to entering the medical device industry in 1999, Dan spent the majority of his career in various roles at GE and working as a consultant for Booz & Company in Sydney Australia.

    Dan has a Bachelor of Science degree in Mechanical Engineering from the University of Vermont, and a Master of Business Administration from Harvard Business School.

    Dr. Jasmine Cui
    Co-founder, President & CEO of
    Beijing InnoCare Pharma Tech

    Dr. Jasmine Cui is the co-founder, President & CEO of Beijing InnoCare Pharma Tech. Ltd. (InnoCare). Prior to founding InnoCare, Dr. Cui was the General Manager of BioDuro (2011-2015). Her area of responsibility included BioDuro’s overall scientific and operational management, as well as business & resource management. Before BioDuro, Dr. Cui worked at Merck Research Laboratories for 14 years serving as Director of Cardiovascular Diseases where she provided project leadership for delivering >10 drug candidates. She also served as the Chair of Early Development Team for development of drug candidate from preclinical to clinical phase 2a for POC in humans. She also headed the hypertension exploratory biomarker for identifying and developing preclinical and translatable biomarkers in cardiovascular diseases.

    Dr. Cui received her Ph.D. in biology from Purdue University and completed her postdoctoral fellowship at Howard Hughes Medical Institute affiliated with the University of Michigan. Dr. Cui was the 17th SAPA President with the honor to be the first female President in the history of SAPA. Currently, Dr. Cui is the president of SAPA China.

    Dandan Dong
    Principal
    Vivo Capital

    Dandan Dong, Ph.D., is a principal of Vivo Capital with a background in academic medical research and translational science. She has more than eight years’ experience in healthcare investment in both the United States and China. The key person in Vivo’s cross-border strategy, she has led the execution of multiple transactions in both territories. Dr. Dong is also the general partner member and chief investment officer of Vivo’s early-stage investment vehicle, Vivo PANDA Fund.

    She has conducted research in infectious disease and immunology and as the first author has published her research in multiple peer-reviewed journals, including Infection and Immunity and the Journal of Infectious Disease.

    Dr. Dong holds a doctorate in biomedical science from Fudan University. She completed the predoctoral fellowship program at New York University School of Medicine in 2008.

    William (Skip) Fisher
    Partner
    DLA Piper

    Skip has practiced intellectual property (IP) law in the U.S., China and internationally for over 20 years. Skip’s practice focuses on IP asset management and strategy, licensing and technology transfer, and IP enforcement and litigation. Skip works in all areas of intellectual property with an emphasis on patents and trade secrets.

    Skip helps companies establish and implement strategies for procuring, commercializing and enforcing their IP rights, and for minimizing risk to their IP assets, in China, the U.S. and globally. He advises companies on Chinese, U.S. and international IP laws; conducts all aspects of IP due diligence, including assessing validity and infringement risk; negotiates and drafts IP and technology licenses, collaboration and co-development contracts and other commercial agreements; and represents companies in high-stakes IP litigation and enforcement actions.

    Over the years, Skip has worked in a variety of industry sectors, including biotechnology, chemical, medical devices, pharmaceutical, mechanical and industrial products, computer networks, electronics, aerospace and automotive. Most recently, he has helped a Chinese pharmaceutical company conclude several cross-border drug in-licensing transactions, has conducted IP due diligence and negotiated license agreements for a Chinese private equity firm in connection with its investments in two technology start-up companies, and has advised one of the world’s largest medical device/technology companies on patent and other IP issues in connection with its potential acquisition of a Chinese company and potential licensing of technology/IP from another Chinese company.

    Ellen Jiang
    Founder and President
    Ramed (Beijing) Medical Technology Co., Ltd.

    Ellen Jiang is the founder and president of Ramed (Beijing) Medical Technology and the co-founder of Ramed Biosciences, LLC, where she leads the company’s regulatory service for the medical device industry. She has 26 years of work experience in healthcare, 22 of which specialized in regulatory affairs, quality system, and regulatory compliance and government affairs for medical devices. She is also actively involved in the work for product standards.

    Previously, she was director of regulatory affairs and compliance for BD China and director of regulatory affairs and compliance for Thermo Fisher Scientific. Her team received a global CEO award in 2015, as well as several “best support team” awards while at BD China.

    Ms. Jiang holds a bachelor’s degree in clinical medicine and an executive master of business administration degree. Over the past 22 years, she has also undergone a variety of professional trainings on medical device regulations.

    Kewen Jin, M.D.
    Managing Partner
    Serica Capital

    Kewen Jin is a serial entrepreneur and investor in the China life science industry. He is currently Managing Partner / co-founder of Serica Capital, a China-based medtech fund. Over the last 15 years, Kewen has co-founded and served as CEO / key executives of several companies in CRO, drug development , and medical device, most recently co-founder / CEO of SyMap, a leading device company in the Renal Denervation for Hypertension area.

    He has served as an advisor to numerous pharmaceutical / medtech companies, consulting / investment firms, notably Gates Foundation and Advent, the global PE. He advised two leading life science parks in China, Shanghai Zhangjiang and Suzhou Biobay, in developing and implementing strategic plan. He was the founding Chair of the Shanghai CRO Association.

    He was a marketing and international operation executive with Wyeth from 1993 to 2000, in the U.S. and China. He was the Chairman of Board of The BayHelix Group from 2014 to 2017, an organization of Chinese life sciences business leaders in China and the U.S. He was trained in medicine (Shanghai Jiaotong University School of Medicine), molecular biology (Rockefeller), and finance (Columbia).

    Portia Ku
    Partner
    O'Melveny & Myers LLP

    Portia Ku is an accomplished corporate transactional lawyer who specializes in capital markets, mergers and acquisitions, venture capital and private equity financings. Portia’s clients include public and private companies that span a variety of industries, including the technology, life sciences, healthcare, and financial services sectors. Portia has successfully completed a myriad of deals on behalf of her clients. She applies her expansive technical experience, strategic execution, and dedication to guide clients through highly complex transactions while ultimately helping them achieve their corporate goals.

    James Li
    Chief Executive Officer and Co-founder
    JW Therapeutics

    James Li, MD, is the CEO and co-founder of JW Therapeutics, a joint-venture company set to revolutionize cancer treatment in China.

    Previously, he was a partner at KPCB China and the founding general manager of Amgen China, where he led the effort to expand the company’s business to Chinese patients. Prior to Amgen, he was a partner at Kleiner Perkins Caufield & Byers’ life science practice. Before that, he spent 15-plus years with Merck & Co., where he held leadership positions in clinical research, regulatory affairs, new product development and franchise management. He was instrumental in obtaining regulatory approvals of Merck vaccines across the Asia-Pacific region, successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s largest franchise in Asia.

    Dr. Li holds a medical degree from Shanghai Medical University and a master of science degree in microbiology from the University of Montana.

    Qiang Li
    Co–Regional Managing Partner, Asia
    Co–Country Managing Partner, China

    DLA Piper

    Qiang Li has been practicing law in Hong Kong and Shanghai since 1997. His practice covers mergers and acquisitions, private equity investment and corporate finance. He advises multinational and Chinese corporate and fund clients on their cross-border M&A and direct investment projects.

    He recently advised Sanpower Group on its $820 million acquisition of Valeant Pharmaceuticals’ prostate cancer cell treatment business Dendreon; as a follow-up, he further advised A-share listed Nanjing Xinjiekou Department Store on its acquisition of the Dendreon businesses. He also advised Sinocare Inc. on its $290 million acquisition of PTS Diagnostics and its $273 million acquisition of Nipro Diagnostics.

    Mr. Li frequently counsels international investors on China’s foreign investment legal regime and has served as counsel to the board of the American Chamber of Commerce in Shanghai. He is the founder of the Shanghai-based Global History Club.

    Donnie McGrath
    Chief of Corporate Strategy and Business Development
    Biohaven Pharmaceuticals

    Donnie McGrath, MD, MPH, is chief of corporate strategy and business development at Biohaven Pharmaceuticals, a clinical development-stage public company based in New Haven, Connecticut. He has more than 25 years of clinical research and pharmaceutical business development experience.

    Previously, he was vice president of business development and head of search and evaluation at Bristol-Myers Squibb. During his tenure, the group executed more than 75 major transactions in the therapeutic areas of oncology, neuroscience, cardiovascular, fibrosis, immunoscience, virology and genetically defined diseases. Dr. McGrath was responsible for overseeing the company’s venture capital investment portfolio and provided leadership for all global external partnering activities.

    Prior to that, he was a physician-researcher at the Tufts Medical Center Geographic Medicine and Infectious Diseases division and an assistant professor of medicine at Tufts University School of Medicine. From 2002 to 2004, he was based at the Africa Centre for Health and Population Studies in KwaZulu-Natal, South Africa.

    Jacob Parker
    Vice President, China Operations
    US-China Business Council

    Jacob Parker is the vice president of China operations at the US-China Business Council. In this role he manages USCBC’s two offices in Beijing and Shanghai and oversees the development and execution of China-based research, reporting, and programming on trends of importance to US businesses operating in China. He has worked on a variety of international public and private projects throughout his career. Before joining USCBC, Jacob worked as a program manager at Philips Healthcare where he oversaw implementation of ExIm Bank, Nordic Investment Bank, and Ashra Bank international government loan projects for developing medical infrastructure in China. Prior to that, as the director of operations of the USA Pavilion Shanghai Expo 2010, Jacob was responsible for the set-up, maintenance, and general operation of the pavilion, and for sharing American culture and values with the more than 7 million visitors during the six months of operation.

    Konstantin Poukalov
    Executive Vice President and Chief Financial Officer
    Kadmon Holdings, Inc.

    Konstantin Poukalov has been executive vice president and CFO at Kadmon Holdings since 2014. From 2012 to 2014, he served as its vice president of strategic operations.

    From 2009 to 2012, Mr. Poukalov was a member of the healthcare investment banking group at Jefferies LLC, focusing on companies across the life sciences and biotechnology sectors. Prior to Jefferies, from 2006 to 2009 he was a member of UBS Investment Bank, focusing on the healthcare industry.

    He currently serves on the advisory board of Pencils of Promise, a nonprofit organization that aims to increase access to high-quality education in the developing world.

    Mr. Poukalov holds a bachelor’s degree in electrical engineering from Stony Brook University.

    David M. Sabow
    Group Head of Life Sciences, Client Funds and Bank Products
    Silicon Valley Bank

    David Sabow is the head of Silicon Valley Bank’s life science and healthcare practice, client funds and products. He manages deal teams across the country, drives the sales and marketing strategy, assists with the structuring of complex credits and presents regularly at global industry conferences. With more than 15 years of life science and healthcare finance experience, David’s background includes structuring senior and subordinated debt, IPOs, follow-on offerings, mergers & acquisitions and strategic advisory roles across the sector.

    Prior to joining Silicon Valley Bank, David spent nine years in the life science investment banking practice at Canaccord Genuity, with responsibility for both domestic and international deals across the life science and healthcare spectrum, specializing in public financings and M&A transactions with an aggregate deal value in excess of $1 billion. Before Canaccord, David worked as a relationship manager with U.S. Bank.

    David graduated with distinction from Santa Clara University, and recently completed the executive program at Dartmouth’s Tuck School of Business, focusing on Leadership and Strategic Impact. He lives in Needham, Massachusetts with his wife and three children.

    Greg B. Scott
    Founder and Chairman
    ChinaBio® Group

    Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on investment and partnering, including the ChinaBio® Partnering Forum which draws over 1000 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today, a widely read newsletter covering the China life science industry. He is considered a leading expert on China’s life science industry, and is frequently quoted in the media including the Wall Street Journal, Financial Times, Bloomberg, BioWorld, etc. Headquartered in Shanghai, ChinaBio® has staff in San Diego, Palo Alto, and Basel, Switzerland.

    John Wang
    Managing Director
    CVCapital

    John Wang has 22 years Healthcare related experience. He completed 30 M&A and private placement transactions in healthcare related sectors, including Bio-pharmaceutical, Med-Tech, Healthcare Services, etc. He developed close relationship with many large and medium-sized healthcare companies, and successfully closed seven co-investment projects. He was a EMBA, from Washington University in St. Louis and Fudan University and double degree in Industrial and Electrical Automation and Management, Jiangsu Science and Technology University.

    Jonathan Wang
    Co-founder and Senior Managing Director
    OrbiMed Asia

    Johnathan Wang has more than 20 years of healthcare and life science experience, spanning investment, entrepreneurship, finance and research. ChinaVenture named him one of the top 10 healthcare investors in China. He has invested in many successful companies, including Zai, Genewiz, ForteBio and EA. He is a co-founder and former chairman of BayHelix, a premier organization of Chinese healthcare business leaders.

    Under the supervision of Nobel Laureate Eric Kandel, Dr. Wang obtained a Ph.D. in molecular neurobiology from Columbia University. He was awarded the Howard Hughes Medical Institute Research Fellowship at Columbia. He also holds an master of business administration degree from Stanford University.

    Jonathan Wang
    SVP, Head of Business Development
    Zai Lab

    Jonathan Wang is our head of business development since 2014. Prior to joining Zai Lab, Mr. Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to 2011, Mr. Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr. Wang also gained financial transactional experience at Goldman Sachs Investment Banking. Mr. Wang received a master of business administration in healthcare management from Wharton Business School.

    Alex Ye
    Vice President, Global Business Development
    Adlai Nortye

    Alex Ye is the vice president of global business development at Adlai Nortye. He has a strong track record as a business developer in the global pharmaceutical industry.

    Previously, he was vice president of business development for inVentiv Health Global Commercial, a fully integrated, end-to-end global biopharma solution company, where he played an instrumental role in the commercial launch of some of the brand products in the U.S. market. He also led a China commercial business unit and built the medical education teams in China for several MNC partners. Prior to inVentiv Health, he was regional sales manager for GenScript in New Jersey, as well as the business development director for Patheon (now part of Thermo Fisher), a global leading biologics CMO in the United States.

    Chen Yu
    Managing Partner
    Vivo Capital

    Chen Yu, M.D., M.B.A. is a Managing Partner based in Palo Alto who joined Vivo in 2004. At Vivo, Dr. Yu invests in both private and public pharmaceutical and medical device companies in the US and China. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including Sagent Pharmaceuticals (SGNT), China KangHui (KH), and aQuantive (AQNT). Notably, Dr. Yu has played a leading industry role in facilitating cross border deals between emerging market and US healthcare companies. As Chief Business Officer at China KangHui (KH), a leading China based orthopedic company, he helped take the company public on the New York Stock Exchange in 2010 and ultimately led negotiations during the sale to Medtronic for $816 MM in 2012. Dr. Yu also served as Chief Operating Officer at Sagent Pharmaceuticals (SGNT), which was acquired by Nichi-Iko for $763 M in 2016. Dr. Yu currently serves or has served on the boards of several life science companies in both the US and China, including Kala (KALA), Nabriva (NBRV), Rempex (Acquired by MDCO), Outpost Medicine(US), Sentre Heart (US), Jian Rui Bao (China), and GMT Medical (China). Other representative investments include Zai Labs, Trauson (acquired by Stryker for $764 MM), Durata (acquired by Actavis for $675M), RiverVision (acquired by Horizon), Achillion (ACHN), Cubist (CBST), and Ocera (OCRX).

    Dr. Yu is also active in the community, including serving on the California Leadership Council for the Nature Conservancy and the Fund Development Committee for the California chapter of the Alzheimer’s Association. He was also previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.

    Dr. Bing Yuan
    Chief Business Officer
    CStone Pharmaceuticals

    Dr. Bing Yuan is currently Chief Business Officer at CStone Pharmaceuticals, responsible for business and commercial related functions, including BD&L, corporate strategy, public relations, government affairs and new product launch. He is a seasoned business executive with extensive experience in business development and marketing strategy, made significant contributions to 9 global oncology brands. Before joining CStone, he was Executive Director and Global Lead of Oncology BD at Merck (MSD). He focused on expanding Merck's leadership position in cancer immunotherapy, and successfully achieved 34 M&A, licensing and Keytruda collaboration deals. Before Merck, he was Global Head of Life Cycle Strategy and Executive Director at Novartis Oncology, responsible for Glivecand Afinitor brand life cycle strategy. He played a key role in global launch of Zykadia in ALK+ lung cancer and was a core deal team member that in-licensed Jakavi from Incyte. He was three-time Novartis Oncology President Award recipient. He also served as Global Oncology Marketing Lead at Eisai in the past, managing entire oncology portfolio. Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, a MBA from Cornell University and B.S. of Biochemistry from Nanjing University.

    William Zarit
    Senior Counselor
    The Cohen Group

    The Honorable William Zarit advises major Chinese companies on how to navigate the US investment market, and helps US multinationals working in the Chinese commercial environment. He also serves as Chairman of the Board for the American Chamber of Commerce in China.

    Until May 2014, Mr. Zarit was Minister for Commercial Affairs at the US Embassy in Beijing, overseeing the US Department of Commerce’s trade promotion and trade policy activities in its operations in Beijing, Chengdu, Guangzhou, Shanghai, and Shenyang. He retired with the rank of Career Minister.

    Prior to his posting to Beijing, Mr. Zarit was Deputy Assistant Secretary, International Operations, for the US Commercial Service, overseeing Commercial Sections in US Embassies and Consulates worldwide. He previously served as US Commercial Service’s Regional Director for East Asia/Pacific, Senior Commercial Officer at the US Embassy in Kuala Lumpur, Malaysia, Deputy Senior Commercial Officer at the US Embassy in Beijing, and Deputy Senior Commercial Officer at the American Institute in Taiwan.

    Before joining the US Commercial Service, Mr. Zarit was Economic and Commercial Program Officer for the New York-based National Committee on US-China Relations. Prior to that, he served as Marketing Manager/China for the California-based telecommunications firm Pacific Telesis International, preceded by his work as Project Manager for the high-tech marketing firm China Business Associates. Both positions were based in Beijing. Mr. Zarit also served as Mandarin Chinese Interpreter for the US State Department Language Services.

    He earned an MBA with Honors from the University of California, Berkeley, and a BA with Honors in Political Science from Miami University, Oxford, Ohio.

    Dr. Jimmy Zhang
    Founder and Chief Executive Officer
    AeonGen

    Jimmy Zhang, Ph.D., is the founder and CEO of AeonGen, a quantum biotech company.

    Previously, he was with Johnson & Johnson Innovation, where he led the transactional and partnership management activities and strategy in the Asia-Pacific Region in pharmaceuticals, medical devices and diagnostics, and consumer products. Before that he was with Merck & Co. and a member of the Merck Research Lab (China) senior leadership team. He was also a board director of BeiGene (Beijing) and an advisory board member of Cenova Ventures.

    He has published in Cell, Nature, Neuron, and the Journal of Biological Chemistry and holds multiple patents.

    Dr. Zhang holds a bachelor of science degree in biochemistry from Nanjing University and doctorate in biomedical sciences from UT Southwestern Medical Center in Dallas, where he worked closely with three Nobel laureates. While studying at the MIT Sloan School of Management, he was elected treasurer of the MIT Graduate Student Council.

    Kezhou Zhang
    Vice President
    Novo Nordisk

    Kezhou Zhang, MD, Ph.D., joined Novo Nordisk A/S in 2002 and worked as senior medical advisor and principal scientist for modern insulins. In 2008, he joined Novo Nordisk China as the head of marketing. Since 2011, he has been vice president of clinical development, medical and regulatory affairs for Novo Nordisk China.

    Dr. Zhang’s interests include functional analysis of therapeutic protein and diabetes clinical research. His research results have been published in such top peer-reviewed journals as Proceedings of the National Academy of Sciences, Diabetes Care, the FASEB Journal, the American Journal of Pathology, and the European Journal of Immunology. He also owns an international patent of a novel protein.

    Dr. Zhang holds a medical degree in clinical medicine from Shanghai Second Medical College and a doctorate in biomedicine from Helsinki University, as well as a master of business administration degree from Scandinavian International Management Institute in Copenhagen.

    Fisher Zhou
    Head of Healthcare Greater China of Corporate Finance
    CLSA

    Mr. Zhou is Head of Healthcare Greater China of Corporate Finance at CLSA. With over 10 years of experience in corporate finance in China and Hong Kong capital market, Mr. Zhou's prime focus is on medical services, medical devices and pharmaceutical, including origination, industry research and project execution across these sectors. He had led Kang Ning Hospital’s listing in HK in 2015 with proceeds of USD100m. He led or attended as a core member in deal of 3S Bio’s IPO, Universal Medical’s IPO, Lvye Pharm’s IPO.

    Mr. Zhou holds a Master in Finance from Guanghua School of Management, Peking University.

  3. Hotel

    2018 SUMMIT HOTEL

    We invite you to stay at the conference hotel, the Andaz Xintiandi Shanghai, in the vibrant Xintiandi district of Shanghai.

    Andaz Xintiandi Shanghai
    88 Songshan Road, Huangpu District
    Shanghai, China 200021
    Phone: +86 21 2310 1234

    The summit has negotiated special rates for attendees. Please email Hidy Fu at hidy.fu@lycheegroup.com to receive a hotel reservation form to book your accommodations.

  4. Visa Planning Tips

    Visa Planning Tips

    • Allow 4 weeks to complete the steps of the Chinese Visa application process
    • Check the expiration date of your passport and renew immediately if required
    • The Chinese Consulate requires your passport during the Visa application process.

    If you are traveling abroad prior to the Summit, you will need to factor your travel into the timing of your application.

    The length of time to secure a visa depends on the consulate at which the traveler is applying for the visa. And the traveler has to apply at the consulate which has jurisdiction for their state of residence. The consulate in San Francisco advises of a 4 business day turn-around, but they also have an expedited option. This assumes that all documents are in order. To gather all of the relevant documents, we usually estimate 1 week, so in theory the visa can be obtained in about 2 weeks.

    In addition to the Lychee Group China issued invitation letter, which is required by the Chinese Consulate, the traveler should also provide an original letter from their employer stating its financial support of the trip to the 2018 Healthcare Capital & Connections Summit.

    Invitation Letter

    Our conference logistics partner, Lychee Group China will issue the invitation letter required for attendees applying for a Chinese visa.  For Lychee to help issue the invitation letter, you need to:

    Lychee Group China will need 3 days to issue the invitation letter. Please submit the information for the Invitation Letter as soon as possible following Summit registration.

Founding Sponsors

Platinum Sponsors

Gold Sponsors

Strategic Sponsors

The presenters at Healthcare Capital & Connections Summit are independent third parties and are not affiliated with SVB Financial Group. See Terms of Use for more detail.

© 2018 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).